Schedule a Meeting
Download Brochure
Table of Content
February 2025
The global CRISPR technology market size is calculated at USD 5.72 billion in 2024, grew to USD 6.67 billion in 2025, and is projected to reach around USD 26.22 billion by 2034. The market is expanding at a CAGR of 16.54% between 2025 and 2034. The growing genomics and proteomics research, increasing investments, and technological advancements boost the market.
Unlock Infinite Advantages: Subscribe to Annual Membership
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a family of DNA sequences found in the genomes of prokaryotic organisms such as bacteria and archaea. It is a technology that selectively modifies DNA sequences or fixes the mutated gene. It is primarily used in various applications such as basic biological research, the development of biotechnological products, and the treatment of diseases. CRISPR technology is a simple and elegant technique of gene editing as it uses RNA instead of a protein. It significantly reduces the time and cost of the procedure, enhancing its precision and accuracy.
The rising incidences and prevalence of chronic disorders necessitate the development of novel drugs and therapies. Several research organizations adopt advanced technologies to produce advanced products for treating severe, rare genetic disorders. The increasing investments, collaborations, and mergers & acquisitions drive the market. The growing awareness among researchers from developing countries potentiates the use of CRISPR technology. The rising demand for personalized medicines also fuels the market growth.
Artificial intelligence (AI) and machine learning (ML) algorithms can revolutionize CRISPR technology and gene editing techniques. AI and ML enhance CRISPR technology’s precision, accuracy, effectiveness, and adaptability, facilitating genome editing, disease detection, and drug discovery. AI algorithms can assist in designing and predicting guide RNA (gRNA) sequences for CRISPR systems. Integrating AI and ML in CRISPR technology enables the development of novel personalized medicines based on individual genetic profiles. They can detect several mutations, variations, and biomarkers associated with the disease. AI and ML can improve editing efficiency and ensure safety in clinical applications. Hence, AI-enabled CRISPR-based gene editing can overcome the potential challenges of conventional techniques, such as high costs and off-target editing.
Growing Research and Development
The major growth factor of the CRISPR technology market is the growing research and development activities. CRISPR technology is widely used in diverse fields such as life sciences, biomedical research, and clinical settings. Researchers are focusing on finding extended applications for CRISPR technology. Currently, this technology is being investigated for treating chronic bacterial urinary tract infection, protein folding disease (hATTR), inflammatory disease, cancer, cardiovascular disease, HIV/AIDS, diabetes, and autoimmunity. Pharmaceutical and biotechnology companies are evaluating novel products in clinical trials to accelerate time to market approval. The approval of new products strengthens a company’s position in the market. The increasing number of biotech startups and rising funding contribute to the market. The venture capital investment in biotech was £6.96 billion in the third quarter of 2024 globally.
Lack of Trained Professionals
The major challenge of the market is the lack of trained professionals. As CRISPR technology is a rapidly evolving field, there are a limited number of scientists who can perform CRISPR-related experiments. Researchers, especially from underdeveloped and developing countries, are unaware of this latest technology, restricting market growth.
Latest Innovations
The future of the CRISPR technology market is promising, driven by the latest innovations. The burgeoning demand for CRISPR technology facilitates researchers to revolutionize the technology to enhance its overall potential. CRISPR-based therapies are evaluated in in vivo clinical trials for treating orphan diseases. The latest innovations lead to the delivery of CRISPR to a greater variety of tissues. Novel drug delivery systems are being developed to enhance the therapeutic potential of rare genetic disorders. The future of CRISPR technology also involves accelerating the expansion of the CRISPR toolkit to include base editors, prime editors, etc. Prime editing can provide a strategy to develop more powerful gene mutation techniques. Additionally, CRISPR screening can offer great promise in discovering essential cancer genes and therapeutic targets, enabling scientists to discover novel medications.
By type, the product segment held a dominant presence in the CRISPR technology market in 2024. The CRISPR kits and enzymes held a major share of the product segment. They are essential for conducting research based on CRISPR technology. Numerous companies sell kits and reagents to allow researchers to carry out research multiple times. Scientists can also modify their experiments and customize the procedure based on their requirements. Reagents and enzymes are to be refilled to perform novel experiments. Advancements in diagnostics also potentiate the demand for CRISPR kits and enzymes.
By type, the services segment is expected to grow at the fastest rate in the market during the forecast period. The availability of affordable services increases the accessibility of CRISPR gene-editing technology. Services provide accurate and precise outcomes with technical expertise, enabling researchers to focus more on other important aspects. Several research institutions have a lack of skilled professionals to conduct research based on this technology. Hence, services can enhance research capabilities in such institutions.
By application, the drug discovery & development segment led the global CRISPR technology market in 2024. The rising prevalence of rare and genetic disorders necessitates the development of novel drugs to treat such severe disorders. The recent approval of Casgevy, a CRISPR technology-based medicine, has increased the demand for novel drugs based on this technology. CRISPR technology can rapidly identify and validate potential drug targets by precisely manipulating genes within the cells. The growing demand for personalized medicines and growing research and development activities promote the segment’s growth.
By end-user, the pharmaceutical & biotechnology companies segment held the largest share of the market in 2024. The segmental growth is attributed to the availability of suitable infrastructure and the presence of skilled professionals. The increasing investments and market competitiveness also augment the segment’s growth. The growing number of pharma and biotech startups and CRISPR-based startups increases the demand for CRISPR technology. The state-of-the-art research and development facilities and increased focus on novel drugs for genetic disorders fuel the segment’s growth.
By end-user, the academic & research institutes segment is anticipated to grow with the highest CAGR in the CRISPR technology market during the studied years. The growing research and development activities and increasing number of patents based on CRISPR technology propel the segment’s growth. It is estimated that more than 14,000 CRISPR-based patents are filed globally. The increasing public-private partnerships and industry-academia collaborations support the research. Additionally, increasing funding from government and private organizations encourages researchers to advance CRISPR research.
North America dominated the global CRISPR technology market in 2024. Technological advancements and the presence of key players drive the market. Favorable regulatory policies support the market. In 2023, the U.S. FDA approved two new medicines, Casgevy and Lyfgenia, the first cell-based gene therapies for the treatment of sickle cell disease. The increasing investments and favorable government support also contribute to the market. The Government of Canada launched the Canadian Genomics Strategy with an investment of $175.1 million over 7 years, starting from 2024-25. The strategy was made to strengthen Canada’s ability to translate genomics research into real-world applications across key sectors. The availability of state-of-the-art research and development facilities and the increasing number of clinical trials promote the market.
Asia-Pacific is anticipated to grow at the fastest rate in the CRISPR technology market during the forecast period. The rising prevalence of chronic disorders and the increasing geriatric population drive the market. It is estimated that around 10 million people in China suffer from rare diseases, enhancing the need for CRISPR technology. Favorable government policies and increasing investments also contribute to the market. The Chinese and Indian governments make continuous efforts to support genomics research and cell and gene therapy development. The Indian government launched the “National Genome Editing & Training Center” to cater to regional needs and adapt different genome editing methods, including CRISPR-Cas technology. The burgeoning biotechnology sector and the increasing number of startups propel the market.
In October 2024, ERS Genomics Limited announced a non-exclusive CRISPR/Cas9 license agreement with Université de Montréal, granting the university access to its CRISPR/Cas9 patent portfolio. John E. Milad, CEO of ERS Genomics, commented that enabling access to its patent portfolio enabled the launch of screening platforms to uncover new therapeutic targets and ultimately improve healthcare outcomes. The company is eager to see the transformative impact of the university’s work on global medical challenges.
By Type
By Applications
By End-User
By Region
February 2025
February 2025
February 2025
January 2025
Annual Access, Limitless Research! Unlock all market research reports with our annual subscription. Stay on top of market trends and crucial insights year-round!
2500+
Client Queries in 20235000+
Insights Published60+
Consulting Projects Per Year40+
Analysts